Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its lead and only approved product, LYMPHIR (denileukin diftitox-cdxl), is an engineered IL-2 diphtheria toxin fusion protein for adults with persistent or recurrent cutaneous… From the company’s description.
In fiscal 2025, Citius Oncology, Inc. reported a net loss of $24.76M. Operations used $5.49M in cash. Over the twelve months to Jun 30, 2026, revenue was $7.11M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Citius Oncology, Inc. does
In the company’s own words
Citius Oncology, Inc. (Nasdaq: CTOR) is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its lead and only approved product, LYMPHIR (denileukin diftitox-cdxl), is an engineered IL-2 diphtheria toxin fusion protein for adults with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The FDA approved LYMPHIR in August 2024, and the company launched it in December 2025. LYMPHIR is designed to target cells expressing the IL-2 receptor and is administered by intravenous infusion. Citius Oncology aims to commercialize products directly in the United States and work with partners outside the country. For LYMPHIR, it uses a contracted commercial organization and distribution agreements, while third-party manufacturers produce the product. The company is also evaluating LYMPHIR in investigator-led studies as a combination therapy for other cancers, including with pembrolizumab and before CAR-T treatment. Citius Oncology became a standalone publicly traded company through an August 2024 merger and remains majority-owned by Citius Pharmaceuticals.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CRANFORD, NJ
- Fiscal year end
- September
- CIK
- 1851484
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Citius Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Citius Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Citius Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Citius Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Citius Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”